Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 602-611
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.602
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.602
Gender | Age attreatment start | HCV genotype | Immune suppression | Baseline ALT U/L | Baseline RNA × 106 | Time transplant to treatment (m) | Treatment regimen | End of treatment ALT U/L | End of treatment biopsy | ||||
Treatment to biopsy (wk) | Inflammation grade | Fibrosis stage | Other findings | ||||||||||
1 | F | 59 | 1a | MMF, tacrolimus | 57 | 1.3 | 22 mo | SOF/SIM | 18 | 25 | 2 | 1 | |
2 | M | 57 | 1a | Tacrolimus | 12 | 0.3 | 32 d | SOF/RBV | 17 | 22 | 0 | 0 | Mild centrilobular dilatation with focal hemorrhage |
3 | M | 59 | 1a | MMF, tacrolimus | 85 | 4.0 | 13 mo | SOF/RBV > SOF/SIM | 11 | 32 | 2 | 0 | |
4 | M | 61 | 1a or 1b | Tacrolimus | 20 | 0.1 | 5 mo | SOF/RBV | 16 | 22 | 3 | 0 | |
5 | M | 68 | 1a or 1b | Tacrolimus | 44 | 1.2 | 8.5 yr | SOF/RBV | 18 | 25 | 1 | 3 | |
6 | F | 76 | 1a | Tacrolimus | 20 | 10.6 | 5.5 mo | SOF/SIM | 48 | 25 | 2 | 0 | Histocytes granuloma |
7 | F | 80 | 1a | Tacrolimus | 12 | 5.2 | 18 yr | SOF/SIM | 15 | 24 | 3 | 2 | |
8 | M | 62 | 1a | MMF, tacrolimus | 166 | 1.7 | 43 d | SOF/RBV | 9 | 30 | 1 | 0 | Steatosis (< 5%) |
9 | M | 60 | 3a | Tacrolimus, prednisone | 23 | 0.9 | 4 mo | SOF/RBV | 82 | 33 | 1 | 0 | Rare councilmen bodies |
10 | M | 58 | 1a | Tacrolimus | 25 | 1.7 | 20 mo | SOF/RBV | 30 | 25 | 4 | 3 | Mild TCMR cannot be ruled out |
11 | M | 53 | 3a | Cyclosporine | 78 | 5.2 | 4.5 yr | SOF/RBV | 37 | 23 | 4 | 2 | Mild TCMR cannot be ruled out. Two portal tracts show non-necrotizing granulomas |
12 | F | 61 | 2b | Tacrolimus | 43 | 7.6 | 6 mo | SOF/RBV | 34 | 20 | 2 | 1 | |
13 | M | 65 | 1a | Tacrolimus | 94 | 2.0 | 7.5 yr | SOF/RBV > SOF/SIM | 14 | 29 | 2 | 2 | Mild absence of bile ducts |
- Citation: Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB. Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy. World J Hepatol 2022; 14(3): 602-611
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/602.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.602